Biocardia
BCDA
Biocardia (BCDA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.13
- EPS estimate
- −$0.18
- EPS surprise
- +27.78%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 12, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 12, 2026 | −$0.18 | −$0.13 | +27.78% | $0.00 | SEC |
| Q1 2026 | May 15, 2026 | −$0.17 | −$0.21 | −27.27% | $0.00 | SEC |
| Q4 2025 | Mar 24, 2026 | −$0.17 | $0.00 | +100.00% | $0.00 | SEC |
| Q3 2025 | Nov 12, 2025 | −$0.23 | −$0.24 | −4.35% | $0.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.50 | −$0.40 | +20.00% | $0.00 | SEC |
| Q1 2025 | May 14, 2025 | $0.00 | −$0.59 | +0.00% | $0.00 | SEC |
| Q4 2024 | Mar 26, 2025 | −$0.63 | −$0.06 | +90.40% | $25,000.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$1.19 | −$0.61 | +48.74% | $0.00 | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.10 | −$0.88 | −780.00% | $3,000.00 | SEC |
| Q1 2024 | May 14, 2024 | −$3.00 | −$1.35 | +55.00% | $55,000.00 | SEC |
| Q4 2023 | Mar 27, 2024 | −$1.13 | −$1.35 | −20.00% | $17,000.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$1.80 | −$1.80 | +0.00% | $357,000.00 | SEC |
| Q2 2023 | Aug 9, 2023 | −$2.35 | −$2.55 | −8.51% | $43,000.00 | SEC |
| Q1 2023 | May 10, 2023 | −$2.40 | −$2.55 | −6.25% | $64,000.00 | SEC |
| Q4 2022 | Mar 29, 2023 | −$2.70 | −$2.55 | +5.56% | $112,000.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$3.41 | −$2.55 | +25.27% | $212,000.00 | — |
| Q2 2022 | Aug 10, 2022 | −$3.72 | −$2.10 | +43.55% | $974,000.00 | — |
| Q1 2022 | May 11, 2022 | −$2.48 | −$2.85 | −15.15% | $60,000.00 | — |
| Q4 2021 | Mar 29, 2022 | −$2.51 | −$3.15 | −25.37% | $80,000.00 | — |
| Q3 2021 | Nov 10, 2021 | −$3.15 | −$2.40 | +23.81% | $821,000.00 | — |
Quarterly revenue
Frequently asked questions
When did Biocardia (BCDA) last report earnings?
Biocardia last reported on Aug 12, 2026, covering fiscal Q2 2026.
Did BCDA beat earnings estimates?
Yes. Biocardia reported EPS of −$0.13 for Q2 2026 against a −$0.18 estimate — a 27.78% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.